About Us

2018 Strategic Plan


Guided by an analysis of the personalized medicine landscape, PMC is focused on 10 priorities in 2018:

A Congressional Personalized Medicine Caucus

To establish an organizing body for the advancement of personalized medicine priorities in the U.S. Congress, PMC will lead the creation of a Congressional Personalized Medicine Caucus. The Caucus will include a bipartisan group of members interested in improving health care through personalized medicine.

Contact: Cynthia A. Bens, Senior Vice President, Public Policy

Ongoing Advocacy for Policies That Support the Future of Personalized Medicine: Through Interactions with U.S. Federal Agencies Including CMS and FDA

To ensure that policy decisions are made with the future of personalized medicine in mind, PMC will continue to liaise with officials at the Centers for Medicare and Medicaid Services and the U.S. Food and Drug Administration to support policies that will advance the field. Engagement may take the form of comment letters, meetings between PMC members and agency officials, public statements, or any other means that will advance the Coalition’s policy agenda.

Contact: Cynthia A. Bens, Senior Vice President, Public Policy

Public Perspectives on Personalized Medicine: A Survey of U.S. Public Opinion

To underline the ongoing demand for education about personalized medicine’s potential, PMC has partnered with GenomeWeb to commission Public Perspectives on Personalized Medicine, a representative survey of Americans that assesses their awareness of personalized medicine, their reactions to value propositions based on the field’s ability to improve the quality and cost of their health care, and any concerns related to ethics, privacy and access. PMC will release the survey results in 2018 at the National Press Club in Washington, D.C.

Contact: Christopher J. Wells, M.P.A., Vice President, Public Affairs

Personalized Medicine at FDA: 2017 Progress Report

To highlight the ongoing prevalence of personalized medicine approvals at FDA, PMC will publish definitive statistics on the percentage of new drug approvals that were personalized medicines in 2017. PMC’s Personalized Medicine at FDA: 2016 Progress Report demonstrated that in 2016, for the third year in a row, personalized medicines accounted for more than 20 percent of the new molecular entities the agency approved.

Contact: Daryl Pritchard, Ph.D., Senior Vice President, Science Policy

The Clinical and Economic Value of Next-Generation Sequencing: A Peer-Reviewed Journal Article

Recognizing the need for evidence underlining the value of next-generation sequencing, PMC plans to publish peer-reviewed research showing that the technology would yield significant clinical and economic benefits if it were fully integrated into the health care system. The study will show that using next-generation sequencing test results to guide therapy selection can improve outcomes and make the health system more efficient.

Contact: Daryl Pritchard, Ph.D., Senior Vice President, Science Policy

The Clinical Implementation and Value of Precision Medicine at Three Distinct Institutions: A Peer Reviewed Journal Article

To draw attention to the benefits of holistically integrating personalized medicine in clinical settings, PMC will coauthor a peer-reviewed research paper in a special thematic issue of Health Affairs that shows how the integration of personalized treatment approaches has already led to clinical and economic benefits for three pioneering institutions. The paper will demonstrate that personalized medicine, when fully integrated into clinical care, provides benefits to both patients and the health system.

Contact: Daryl Pritchard, Ph.D., Senior Vice President, Science Policy

An Introduction to Informational Genetic Testing: A Consumer Guide to DNA-Based Health Information Testing

Given the renewed interest in consumer services that promise to deliver actionable information based on genetic sequencing results, PMC will update and republish its Introduction to Informational Genetic Testing, which serves as a resource for those who want to learn more about the value of genetic testing backed by scientific evidence.

Contact: Daryl Pritchard, Ph.D., Senior Vice President, Science Policy

Ongoing Analysis of Trends in Personalized Medicine: Published in the PMC Member Update and Personalized Medicine in Brief

To keep members informed about the significance of 2018 news developments to the future of personalized medicine, PMC will continue to publish regular analyses of trends in the field. These analyses will include the monthly Member Update e-newsletter as well as the Coalition’s bi-annual print newsletter, Personalized Medicine in Brief, and an updated version of The Personalized Medicine Report.

Contact: Christopher J. Wells, M.P.A., Vice President, Public Affairs

Ongoing Representation of Key Personalized Medicine Topics at Prominent Industry Conferences: Via Initiatives Including the “PMC/BIO Personalized Medicine & Diagnostics Track” at the 2018 BIO Convention and a PMC-Led Panel Discussion at the 2018 Molecular Medicine Tri-Conference

To ensure that prominent industry conferences continue to explore key personalized medicine topics in 2018, PMC will partner with conference organizers to develop sessions that are of significance to the field. These efforts will include a collaboration with BIO on the “PMC/BIO Personalized Medicine & Diagnostics Track” at the 2018 BIO Convention in Boston and with the Cambridge Healthtech Institute on a panel discussion at the 2018 Molecular Medicine Tri-Conference in San Francisco.

Contact: Kayla Smith, Director, Membership & Development

The 14th Annual Personalized Medicine Conference

To examine the landscape and outlook for personalized medicine, PMC will organize the 14th Annual Personalized Medicine Conference at Harvard Medical School. The conference will explore the most significant trends in science, business and policy, and will guide the Coalition’s next steps in education and advocacy.

Contact: Christopher J. Wells, M.P.A., Vice President, Public Affairs